3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Active not recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Conditions
Breast Neoplasms
9
Prostatic Neoplasms
6
Neoplasms by Site
2
Neoplasms
2
Neoplasm Metastasis
2
Breast Diseases
2
Skin Diseases
1
Salivary Gland Neoplasms
1
Ovarian Neoplasms
1
Metastatic Neuroendocrine Prostate Cancer
1
Metastatic Castration-Resistant Prostate Cancer
1
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
1
Advanced Prostate Cancer
1
Interventions
exemestane
4
entinostat
4
Fulvestrant
4
ribociclib
3
palbociclib
3
abemaciclib
3
Anastrozole
3
Trastuzumab
2
Letrozole
2
Gonadotropin-Releasing Hormone
2
AZD9833
2
tucatinib
1
trastuzumab deruxtecan
1
taxane
1
pertuzumab
1
pembrolizumab
1
ipatasertib
1
figitumumab
1
elacestrant
1
dactolisib
1
atezolizumab
1
Watchful Waiting
1
Trabectedin
1
Tamoxifen
1
STX-478
1
RAD1901
1
Paclitaxel
1
Metformin
1
Lapatinib
1
Imlunestrant
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Breast Diseases
×
Gonadotropin-Releasing Hormone
×
Clear all
NCT04964934
2026-04-21
SERENA-6
AstraZeneca
Phase 3
Active not recruiting
315 enrolled
NCT04711252
2025-10-14
SERENA-4
AstraZeneca
Phase 3
Active not recruiting
1,370 enrolled